SA
TWST icon

Strategic Advocates’s Twist Bioscience TWST Stock Holding History

Strategic Advocates’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$182K Buy
1,773
+13
+0.7% +$846 0.71% 33
2026
Q1 		$83.6K Buy
1,760
+693
+65% +$31.1K 0.37% 59
2025
Q4 		$34.3K Buy
1,067
+906
+563% +$28.3K 0.01% 232
2025
Q3 		$4.53K Buy
+161
New +$4.88K ﹤0.01% 421

Other funds holding TWST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Strategic Advocates's TWST Position: Q2 2026 in Review

Strategic Advocates increased its Twist Bioscience (TWST) stake by 0.74% in Q2 2026, buying an estimated $846 and bringing the position to 1,773 shares worth $182K. The position accounts for 0.71% of the portfolio, ranked #33.

Strategic Advocates first reported a position in TWST in Q3 2025 and has held it in 4 quarters since. 337 funds tracked by Wall St. Rank hold TWST as of Q2 2026.

  • Strategic Advocates held 1,773 shares of Twist Bioscience worth $182K as of Q2 2026.
  • Strategic Advocates bought 13 Twist Bioscience shares in Q2 2026, an estimated $846.
  • Twist Bioscience made up 0.71% of Strategic Advocates's portfolio in Q2 2026, its #33 holding.
  • Strategic Advocates first reported a position in Twist Bioscience in Q3 2025 and has held it in 4 quarters since.
  • 337 funds tracked by Wall St. Rank held Twist Bioscience as of Q2 2026.

Based on Strategic Advocates's 13F filing for Q2 2026, filed 13 Aug 2026.